BACKGROUND
HKG Epitherapeutics Inc. was founded in 2016 by Prof. Moshe Szyf, a world pioneer in the exciting and rapidly emerging science of Epigenetics. With a strong dedication to harnessing the untapped power and possibilities of Epigenetics, HKG Epitherapeutics is a Hong Kong-based company that operates its research and diagnostic lab in Hong Kong.
As part of our commitment to advancing the field of Epigenetics, HKG Epitherapeutics is planning to expand its operations by establishing “next generation” epigenetic diagnostic labs in several countries. This expansion will allow us to bring our cutting-edge research and accurate diagnostic tests closer to individuals worldwide, enabling early detection of cancer and promoting healthy aging.
We believe that by combining the expertise of our team, led by Prof. Moshe Szyf, and the science of Epigenetics, we can revolutionize the field of personalized medicine and contribute to improving healthcare outcomes on a global scale.
With our CLIA-registered (CLIA number: 99D2281144) and CAP-accredited laboratory, HKG Epitherapeutics maintains the highest standards of quality and accuracy in our epigenetic diagnostic services. We are committed to providing researchers, healthcare professionals, and individuals with state-of-the-art DNA methylation analysis tools and services to support their important work in understanding and utilizing the power of Epigenetics.
Join us on this journey as we continue to develop novel tools for early cancer detection, promote healthy aging, and advance the clinical study of Epigenetics.
Together, let’s unlock the potential of Epigenetics and pave the way for a healthier future.
MISSION
With an emphasis on the evolving markets in Euro-Asia and our immediate focus on tests, prevention and early treatment for common diseases such as cancer, our mission is to positively impact the healthcare, well-being, quality of life and promoting healthy aging for large populations worldwide.
Simply stated, the science of Epigenetics centers on DNA Methylation, a simple biochemical process that changes a mark on your DNA when cancer or other catastrophic diseases may develop.
At HKG Epitherapeutics, we are dedicated to helping researchers advance the clinical study of Epigenetics by providing state-of-the-art DNA methylation analysis services.
FOCUS ON PREVENTION. THE CHALLENGE
Our primary goal is to develop tools that detect diseases early, and these tools must meet the following criteria:
- Accurate: Our tests aim to provide reliable and precise results, ensuring accurate detection and diagnosis.
- Cost effective: We strive to make our tests affordable and accessible, ensuring that early disease detection is within reach for a larger population.
- High throughput: Our diagnostic tools are designed to process a large volume of samples efficiently, allowing for faster and broader testing.
- Geographically versatile: We aim to develop tests that can be utilized in diverse geographic areas, making early disease detection accessible to individuals worldwide.
While the company is new, Szyf’s three decades of ground-breaking research and cutting-edge innovations in Epigenetics — how it occurs and how it is passed from generation to generation — has already disrupted medical science with its potential to detect, diagnose, prevent, or cure diseases.
HKG Epitherapeutics firmly believes that the ability to measure and diagnose these changes in DNA will not only revolutionize the fight against diseases but also have a profound impact on regulating critical cardiovascular, neurological, reproductive, and detoxification systems.
We are committed to integrating our novel diagnostics into these developing markets, as we believe it will greatly enhance the quality of healthcare for the people of these countries. To achieve this, we are actively seeking diagnostic licensing partnerships in the area as they become available.
We invite you to reach out to us for more information and join our mission to become a major force in the explosive new science of Epigenetics. By becoming our partner and an influencer in global healthcare, together, we can drive significant advancements and improvements in disease prevention, diagnosis, and treatment.
Headquarters
Research and Development
Hong Kong
- Developing the “platform”
- Developing “Next Generation” epigenetic tests for HCC and additional indications.
- Streamlining and automating our processes to enhance efficiency.
- Global clinical trials
- Developing the HKG and global markets.
- Early detection screening services for both the HKG and global markets
Clinical Development
and China Service
Shenzhen, China
- Conduct clinical trials using advanced "Next-Gen" tests.
- Offer diagnostic products and services tailored to the Chinese market.
- Expand and develop the market presence in China.
MTL
Epitherapeutics
Montreal, Canada
- Early detection screening service center planned for North America
- Epigenetic age (EpiAge) service
- Customized DNA methylation service for researchers
